Table 3 Design of experiment for formulations of transdermal patch of Simvastatin
From: Optimization of simvastatin transdermal patch for hyperlipidemia treatment in rat model
Std | Run | Factor A | Factor B | Factor C |
|---|---|---|---|---|
HPMC K100% | ERL 100% | PEG400% | ||
11 | 1 | 1 | 0.1 | 50 |
3 | 2 | 0.2 | 1 | 30 |
4 | 3 | 1.8 | 1 | 30 |
5 | 4 | 0.2 | 0.55 | 10 |
2 | 5 | 1.8 | 0.1 | 30 |
14 | 6 | 1 | 0.55 | 30 |
13 | 7 | 1 | 0.55 | 30 |
12 | 8 | 1 | 1 | 50 |
15 | 9 | 1 | 0.55 | 30 |
10 | 10 | 1 | 1 | 10 |
6 | 11 | 1.8 | 0.55 | 10 |
7 | 12 | 0.2 | 0.55 | 50 |
8 | 13 | 1.8 | 0.55 | 50 |
1 | 14 | 0.2 | 0.1 | 30 |
9 | 15 | 1 | 0.1 | 10 |